Global Tumor Immunotherapy Market Research Report 2023

Published: March 2023

No. of Pages: 113

Price:

Single User License: US $ 2900

Corporate User License: US $ 5800

Report Description
Table of Contents

Highlights
The global Tumor Immunotherapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Tumor Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Tumor Immunotherapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Tumor Immunotherapy in Biopharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Tumor Immunotherapy include Roche, Merck, Novartis, Johnson & Johnson, GlaxoSmithKline, AbbVie, ELI Lilly, Amgen and AstraZeneca, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunotherapy.
The Tumor Immunotherapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Tumor Immunotherapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor Immunotherapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

By Company
- Roche
- Merck
- Novartis
- Johnson & Johnson
- GlaxoSmithKline
- AbbVie
- ELI Lilly
- Amgen
- AstraZeneca
- Bristol-Mysers Squibb
- Kite Pharma
- Adaptimmune
- Altor Bioscience Corporation
- Cellectis
- Juno Therapeutics
- Takara Bio
- Unum Therapeutics
- Sunway
- Junshi Bio
- Cinda Bio
- BeiGene

Segment by Type
- Tumor Infiltrating Lymphocyte (TIL) Treatment
- Engineered T Cell Receptor (TCR) Therapy
- Chimeric Antigen Receptor (CAR) T Cell Therapy
- Natural Killer (NK) Cell Therapy
- Other

Segment by Application
- Biopharmaceutical Company
- Hospital
- Universities And Other Scientific Research Institutions
- Other

By Region
- North America
- - United States
- - Canada
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- - Nordic Countries
- - Rest of Europe
- Asia-Pacific
- - China
- - Japan
- - South Korea
- - Southeast Asia
- - India
- - Australia
- - Rest of Asia
- Latin America
- - Mexico
- - Brazil
- - Rest of Latin America
- Middle East & Africa
- - Turkey
- - Saudi Arabia
- - UAE
- - Rest of MEA

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor Immunotherapy companies competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Tumor Infiltrating Lymphocyte (TIL) Treatment
1.2.3 Engineered T Cell Receptor (TCR) Therapy
1.2.4 Chimeric Antigen Receptor (CAR) T Cell Therapy
1.2.5 Natural Killer (NK) Cell Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Tumor Immunotherapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Biopharmaceutical Company
1.3.3 Hospital
1.3.4 Universities And Other Scientific Research Institutions
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immunotherapy Market Perspective (2018-2029)
2.2 Tumor Immunotherapy Growth Trends by Region
2.2.1 Global Tumor Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tumor Immunotherapy Historic Market Size by Region (2018-2023)
2.2.3 Tumor Immunotherapy Forecasted Market Size by Region (2024-2029)
2.3 Tumor Immunotherapy Market Dynamics
2.3.1 Tumor Immunotherapy Industry Trends
2.3.2 Tumor Immunotherapy Market Drivers
2.3.3 Tumor Immunotherapy Market Challenges
2.3.4 Tumor Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immunotherapy Players by Revenue
3.1.1 Global Top Tumor Immunotherapy Players by Revenue (2018-2023)
3.1.2 Global Tumor Immunotherapy Revenue Market Share by Players (2018-2023)
3.2 Global Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumor Immunotherapy Revenue
3.4 Global Tumor Immunotherapy Market Concentration Ratio
3.4.1 Global Tumor Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunotherapy Revenue in 2022
3.5 Tumor Immunotherapy Key Players Head office and Area Served
3.6 Key Players Tumor Immunotherapy Product Solution and Service
3.7 Date of Enter into Tumor Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor Immunotherapy Breakdown Data by Type
4.1 Global Tumor Immunotherapy Historic Market Size by Type (2018-2023)
4.2 Global Tumor Immunotherapy Forecasted Market Size by Type (2024-2029)
5 Tumor Immunotherapy Breakdown Data by Application
5.1 Global Tumor Immunotherapy Historic Market Size by Application (2018-2023)
5.2 Global Tumor Immunotherapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Tumor Immunotherapy Market Size (2018-2029)
6.2 North America Tumor Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tumor Immunotherapy Market Size by Country (2018-2023)
6.4 North America Tumor Immunotherapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor Immunotherapy Market Size (2018-2029)
7.2 Europe Tumor Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tumor Immunotherapy Market Size by Country (2018-2023)
7.4 Europe Tumor Immunotherapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immunotherapy Market Size (2018-2029)
8.2 Asia-Pacific Tumor Immunotherapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tumor Immunotherapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Tumor Immunotherapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor Immunotherapy Market Size (2018-2029)
9.2 Latin America Tumor Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tumor Immunotherapy Market Size by Country (2018-2023)
9.4 Latin America Tumor Immunotherapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immunotherapy Market Size (2018-2029)
10.2 Middle East & Africa Tumor Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tumor Immunotherapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Tumor Immunotherapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Tumor Immunotherapy Introduction
11.1.4 Roche Revenue in Tumor Immunotherapy Business (2018-2023)
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Tumor Immunotherapy Introduction
11.2.4 Merck Revenue in Tumor Immunotherapy Business (2018-2023)
11.2.5 Merck Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Tumor Immunotherapy Introduction
11.3.4 Novartis Revenue in Tumor Immunotherapy Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Tumor Immunotherapy Introduction
11.4.4 Johnson & Johnson Revenue in Tumor Immunotherapy Business (2018-2023)
11.4.5 Johnson & Johnson Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Tumor Immunotherapy Introduction
11.5.4 GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2018-2023)
11.5.5 GlaxoSmithKline Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Tumor Immunotherapy Introduction
11.6.4 AbbVie Revenue in Tumor Immunotherapy Business (2018-2023)
11.6.5 AbbVie Recent Development
11.7 ELI Lilly
11.7.1 ELI Lilly Company Detail
11.7.2 ELI Lilly Business Overview
11.7.3 ELI Lilly Tumor Immunotherapy Introduction
11.7.4 ELI Lilly Revenue in Tumor Immunotherapy Business (2018-2023)
11.7.5 ELI Lilly Recent Development
11.8 Amgen
11.8.1 Amgen Company Detail
11.8.2 Amgen Business Overview
11.8.3 Amgen Tumor Immunotherapy Introduction
11.8.4 Amgen Revenue in Tumor Immunotherapy Business (2018-2023)
11.8.5 Amgen Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Detail
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Tumor Immunotherapy Introduction
11.9.4 AstraZeneca Revenue in Tumor Immunotherapy Business (2018-2023)
11.9.5 AstraZeneca Recent Development
11.10 Bristol-Mysers Squibb
11.10.1 Bristol-Mysers Squibb Company Detail
11.10.2 Bristol-Mysers Squibb Business Overview
11.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Introduction
11.10.4 Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2018-2023)
11.10.5 Bristol-Mysers Squibb Recent Development
11.11 Kite Pharma
11.11.1 Kite Pharma Company Detail
11.11.2 Kite Pharma Business Overview
11.11.3 Kite Pharma Tumor Immunotherapy Introduction
11.11.4 Kite Pharma Revenue in Tumor Immunotherapy Business (2018-2023)
11.11.5 Kite Pharma Recent Development
11.12 Adaptimmune
11.12.1 Adaptimmune Company Detail
11.12.2 Adaptimmune Business Overview
11.12.3 Adaptimmune Tumor Immunotherapy Introduction
11.12.4 Adaptimmune Revenue in Tumor Immunotherapy Business (2018-2023)
11.12.5 Adaptimmune Recent Development
11.13 Altor Bioscience Corporation
11.13.1 Altor Bioscience Corporation Company Detail
11.13.2 Altor Bioscience Corporation Business Overview
11.13.3 Altor Bioscience Corporation Tumor Immunotherapy Introduction
11.13.4 Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2018-2023)
11.13.5 Altor Bioscience Corporation Recent Development
11.14 Cellectis
11.14.1 Cellectis Company Detail
11.14.2 Cellectis Business Overview
11.14.3 Cellectis Tumor Immunotherapy Introduction
11.14.4 Cellectis Revenue in Tumor Immunotherapy Business (2018-2023)
11.14.5 Cellectis Recent Development
11.15 Juno Therapeutics
11.15.1 Juno Therapeutics Company Detail
11.15.2 Juno Therapeutics Business Overview
11.15.3 Juno Therapeutics Tumor Immunotherapy Introduction
11.15.4 Juno Therapeutics Revenue in Tumor Immunotherapy Business (2018-2023)
11.15.5 Juno Therapeutics Recent Development
11.16 Takara Bio
11.16.1 Takara Bio Company Detail
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Tumor Immunotherapy Introduction
11.16.4 Takara Bio Revenue in Tumor Immunotherapy Business (2018-2023)
11.16.5 Takara Bio Recent Development
11.17 Unum Therapeutics
11.17.1 Unum Therapeutics Company Detail
11.17.2 Unum Therapeutics Business Overview
11.17.3 Unum Therapeutics Tumor Immunotherapy Introduction
11.17.4 Unum Therapeutics Revenue in Tumor Immunotherapy Business (2018-2023)
11.17.5 Unum Therapeutics Recent Development
11.18 Sunway
11.18.1 Sunway Company Detail
11.18.2 Sunway Business Overview
11.18.3 Sunway Tumor Immunotherapy Introduction
11.18.4 Sunway Revenue in Tumor Immunotherapy Business (2018-2023)
11.18.5 Sunway Recent Development
11.19 Junshi Bio
11.19.1 Junshi Bio Company Detail
11.19.2 Junshi Bio Business Overview
11.19.3 Junshi Bio Tumor Immunotherapy Introduction
11.19.4 Junshi Bio Revenue in Tumor Immunotherapy Business (2018-2023)
11.19.5 Junshi Bio Recent Development
11.20 Cinda Bio
11.20.1 Cinda Bio Company Detail
11.20.2 Cinda Bio Business Overview
11.20.3 Cinda Bio Tumor Immunotherapy Introduction
11.20.4 Cinda Bio Revenue in Tumor Immunotherapy Business (2018-2023)
11.20.5 Cinda Bio Recent Development
11.21 BeiGene
11.21.1 BeiGene Company Detail
11.21.2 BeiGene Business Overview
11.21.3 BeiGene Tumor Immunotherapy Introduction
11.21.4 BeiGene Revenue in Tumor Immunotherapy Business (2018-2023)
11.21.5 BeiGene Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Tumor Immunotherapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Tumor Infiltrating Lymphocyte (TIL) Treatment
Table 3. Key Players of Engineered T Cell Receptor (TCR) Therapy
Table 4. Key Players of Chimeric Antigen Receptor (CAR) T Cell Therapy
Table 5. Key Players of Natural Killer (NK) Cell Therapy
Table 6. Key Players of Other
Table 7. Global Tumor Immunotherapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Tumor Immunotherapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Tumor Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Tumor Immunotherapy Market Share by Region (2018-2023)
Table 11. Global Tumor Immunotherapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Tumor Immunotherapy Market Share by Region (2024-2029)
Table 13. Tumor Immunotherapy Market Trends
Table 14. Tumor Immunotherapy Market Drivers
Table 15. Tumor Immunotherapy Market Challenges
Table 16. Tumor Immunotherapy Market Restraints
Table 17. Global Tumor Immunotherapy Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Tumor Immunotherapy Market Share by Players (2018-2023)
Table 19. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2022)
Table 20. Ranking of Global Top Tumor Immunotherapy Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Tumor Immunotherapy Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Tumor Immunotherapy Product Solution and Service
Table 24. Date of Enter into Tumor Immunotherapy Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Tumor Immunotherapy Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Tumor Immunotherapy Revenue Market Share by Type (2018-2023)
Table 28. Global Tumor Immunotherapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Tumor Immunotherapy Revenue Market Share by Type (2024-2029)
Table 30. Global Tumor Immunotherapy Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Tumor Immunotherapy Revenue Market Share by Application (2018-2023)
Table 32. Global Tumor Immunotherapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Tumor Immunotherapy Revenue Market Share by Application (2024-2029)
Table 34. North America Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America Tumor Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Tumor Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe Tumor Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Tumor Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific Tumor Immunotherapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific Tumor Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Tumor Immunotherapy Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America Tumor Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Tumor Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa Tumor Immunotherapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa Tumor Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Tumor Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 49. Roche Company Detail
Table 50. Roche Business Overview
Table 51. Roche Tumor Immunotherapy Product
Table 52. Roche Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 53. Roche Recent Development
Table 54. Merck Company Detail
Table 55. Merck Business Overview
Table 56. Merck Tumor Immunotherapy Product
Table 57. Merck Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 58. Merck Recent Development
Table 59. Novartis Company Detail
Table 60. Novartis Business Overview
Table 61. Novartis Tumor Immunotherapy Product
Table 62. Novartis Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 63. Novartis Recent Development
Table 64. Johnson & Johnson Company Detail
Table 65. Johnson & Johnson Business Overview
Table 66. Johnson & Johnson Tumor Immunotherapy Product
Table 67. Johnson & Johnson Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 68. Johnson & Johnson Recent Development
Table 69. GlaxoSmithKline Company Detail
Table 70. GlaxoSmithKline Business Overview
Table 71. GlaxoSmithKline Tumor Immunotherapy Product
Table 72. GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 73. GlaxoSmithKline Recent Development
Table 74. AbbVie Company Detail
Table 75. AbbVie Business Overview
Table 76. AbbVie Tumor Immunotherapy Product
Table 77. AbbVie Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 78. AbbVie Recent Development
Table 79. ELI Lilly Company Detail
Table 80. ELI Lilly Business Overview
Table 81. ELI Lilly Tumor Immunotherapy Product
Table 82. ELI Lilly Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 83. ELI Lilly Recent Development
Table 84. Amgen Company Detail
Table 85. Amgen Business Overview
Table 86. Amgen Tumor Immunotherapy Product
Table 87. Amgen Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 88. Amgen Recent Development
Table 89. AstraZeneca Company Detail
Table 90. AstraZeneca Business Overview
Table 91. AstraZeneca Tumor Immunotherapy Product
Table 92. AstraZeneca Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 93. AstraZeneca Recent Development
Table 94. Bristol-Mysers Squibb Company Detail
Table 95. Bristol-Mysers Squibb Business Overview
Table 96. Bristol-Mysers Squibb Tumor Immunotherapy Product
Table 97. Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 98. Bristol-Mysers Squibb Recent Development
Table 99. Kite Pharma Company Detail
Table 100. Kite Pharma Business Overview
Table 101. Kite Pharma Tumor Immunotherapy Product
Table 102. Kite Pharma Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 103. Kite Pharma Recent Development
Table 104. Adaptimmune Company Detail
Table 105. Adaptimmune Business Overview
Table 106. Adaptimmune Tumor Immunotherapy Product
Table 107. Adaptimmune Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 108. Adaptimmune Recent Development
Table 109. Altor Bioscience Corporation Company Detail
Table 110. Altor Bioscience Corporation Business Overview
Table 111. Altor Bioscience Corporation Tumor Immunotherapy Product
Table 112. Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 113. Altor Bioscience Corporation Recent Development
Table 114. Cellectis Company Detail
Table 115. Cellectis Business Overview
Table 116. Cellectis Tumor Immunotherapy Product
Table 117. Cellectis Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 118. Cellectis Recent Development
Table 119. Juno Therapeutics Company Detail
Table 120. Juno Therapeutics Business Overview
Table 121. Juno Therapeutics Tumor Immunotherapy Product
Table 122. Juno Therapeutics Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 123. Juno Therapeutics Recent Development
Table 124. Takara Bio Company Detail
Table 125. Takara Bio Business Overview
Table 126. Takara Bio Tumor Immunotherapy Product
Table 127. Takara Bio Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 128. Takara Bio Recent Development
Table 129. Unum Therapeutics Company Detail
Table 130. Unum Therapeutics Business Overview
Table 131. Unum Therapeutics Tumor Immunotherapy Product
Table 132. Unum Therapeutics Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 133. Unum Therapeutics Recent Development
Table 134. Sunway Company Detail
Table 135. Sunway Business Overview
Table 136. Sunway Tumor Immunotherapy Product
Table 137. Sunway Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 138. Sunway Recent Development
Table 139. Junshi Bio Company Detail
Table 140. Junshi Bio Business Overview
Table 141. Junshi Bio Tumor Immunotherapy Product
Table 142. Junshi Bio Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 143. Junshi Bio Recent Development
Table 144. Cinda Bio Company Detail
Table 145. Cinda Bio Business Overview
Table 146. Cinda Bio Tumor Immunotherapy Product
Table 147. Cinda Bio Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 148. Cinda Bio Recent Development
Table 149. BeiGene Company Detail
Table 150. BeiGene Business Overview
Table 151. BeiGene Tumor Immunotherapy Product
Table 152. BeiGene Revenue in Tumor Immunotherapy Business (2018-2023) & (US$ Million)
Table 153. BeiGene Recent Development
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Tumor Immunotherapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Tumor Immunotherapy Market Share by Type: 2022 VS 2029
Figure 3. Tumor Infiltrating Lymphocyte (TIL) Treatment Features
Figure 4. Engineered T Cell Receptor (TCR) Therapy Features
Figure 5. Chimeric Antigen Receptor (CAR) T Cell Therapy Features
Figure 6. Natural Killer (NK) Cell Therapy Features
Figure 7. Other Features
Figure 8. Global Tumor Immunotherapy Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Tumor Immunotherapy Market Share by Application: 2022 VS 2029
Figure 10. Biopharmaceutical Company Case Studies
Figure 11. Hospital Case Studies
Figure 12. Universities And Other Scientific Research Institutions Case Studies
Figure 13. Other Case Studies
Figure 14. Tumor Immunotherapy Report Years Considered
Figure 15. Global Tumor Immunotherapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 16. Global Tumor Immunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Tumor Immunotherapy Market Share by Region: 2022 VS 2029
Figure 18. Global Tumor Immunotherapy Market Share by Players in 2022
Figure 19. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Tumor Immunotherapy Revenue in 2022
Figure 21. North America Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. North America Tumor Immunotherapy Market Share by Country (2018-2029)
Figure 23. United States Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Tumor Immunotherapy Market Share by Country (2018-2029)
Figure 27. Germany Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. France Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. U.K. Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Italy Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Russia Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Nordic Countries Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Tumor Immunotherapy Market Share by Region (2018-2029)
Figure 35. China Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Japan Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. South Korea Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Southeast Asia Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. India Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Australia Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Tumor Immunotherapy Market Share by Country (2018-2029)
Figure 43. Mexico Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Brazil Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Tumor Immunotherapy Market Share by Country (2018-2029)
Figure 47. Turkey Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Saudi Arabia Tumor Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Roche Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 50. Merck Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 51. Novartis Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 52. Johnson & Johnson Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 53. GlaxoSmithKline Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 54. AbbVie Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 55. ELI Lilly Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 56. Amgen Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 57. AstraZeneca Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 58. Bristol-Mysers Squibb Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 59. Kite Pharma Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 60. Adaptimmune Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 61. Altor Bioscience Corporation Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 62. Cellectis Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 63. Juno Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 64. Takara Bio Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 65. Unum Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 66. Sunway Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 67. Junshi Bio Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 68. Cinda Bio Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 69. BeiGene Revenue Growth Rate in Tumor Immunotherapy Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

Write comment about above report:

Published By: QYResearch Group

Product Code: QYResearch Group2315201

Related Reports

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Global Tumor Immunotherapy Market Insights and Forecast to 2028 Tumor Immunotherapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Tumor Immunotherapy market will be able to gain the upper hand as they use the report as a p...
Global Tumor Immunotherapy Market Research Report 2022 Tumor Immunotherapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Tumor Immunotherapy market will be able to gain the upper hand as they use the report as a p...
Global Tumor Immunotherapy Industry Research Report, Growth Trends and Competitive Analysis 2022-2028 Report Overview Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Tumor Immunotherapy estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR ...
Global Tumor Immunotherapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028 The Tumor Immunotherapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market pl...
Global Tumor Immunotherapy Market Growth (Status and Outlook) 2021-2026 According to this latest study, the 2021 growth of Tumor Immunotherapy will have significant change from previous year. By the most conservative estimates of global Tumor Immunotherapy market size (most likely outcome) will be a year-over-year revenu...
Global and Japan Tumor Immunotherapy Market Size, Status and Forecast 2021-2027 Global Tumor Immunotherapy Scope and Market Size Tumor Immunotherapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Immunotherapy market will be ...
Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy Report Includes: - An overview of Tumor Infiltrating Lymphocytes (TILs) for the treatment of metastatic cancer - Discussion of the development of TIL as a treatment option for melanoma and the possibilities to expand this therapy t...

We are on:

Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
- Upto 24 hrs - working days
- Upto 48 hrs max - weekends and public holidays

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *